Monday , January 18 2021

Besides the Brussels stock exchange, "MedTech"



Swiss-born Sequana Medical has developed a pump that can be transplanted into the body to treat liver-related diseases.

Sequana Medical, A medical device company that is actively involved in developing solutions for various diseases announced today, Euronext Brussels IPO.

Once the deal is realigned, you will participate. Biotechnology compartment It is already well-developed in the market, especially the sub-segments of MedTechs are already included. Curetis

and Biocartis

. The two companies have developed a mini-lab to diagnose specific diseases of different cartridges. IBA

You can also belong to this category.

Alfapump

I'm from Switzerland. Installed in GhentSequana Medical is already in the commercial stage in seven European countries. She developed a pump. alfapump We obtained the CE mark for intractable multiple of liver and malignant vengeance. Ascites is an abnormal accumulation of fluid in the abdomen.

With the implanted pump, the system collects the ascites and transports it to the bladder, which is removed naturally through urination. The pump can be installed within one hour under local or general anesthesia, Sequana explains. 650 locations Already done Since April 2018, alfapump has been included in the guidelines of the European Union for the study of nonadrenergic cirrhosis.

Only 3.9 million adults were living in the United States. Chronic liver disease. Recently, NASH, a serious liver disease associated with obesity, has seen significant growth, especially in the United States.

In addition, "MedTech" has also developed a "Direct Sodium Removal, DSR" treatment for over-volume treatment. heart attack. She plans to start the first human study by the end of this year. "Some of the 6.5 million adults in the United States suffer from these deficiencies, and this figure is expected to increase to 8 million, The company says.

Ablynx alumni who attended the board meeting

At this stage, Sequana does not provide details on the amount you are willing to raise, the number of shares offered, the price, and the calendar … As a disadvantage, Ian Crosby, CEO of Biotechnology What will the funds raised be used for?. "The IPO will fund key research in the United States for commercial placement in Europe, the first human study of DSR therapy, and other European clinical programs. "

Sequana Medical is a subsidiary of KBC Securities, Kempen & Co and Mirabaud.Expand the board of directors.. Pierre Soubino Appointed as President Wim Otterbere I will sit as a non-permanent director. The latter was Ablynx's Chief Financial Officer when Sanofi acquired EUR 3.9 billion.


Source link